Drug development has systems for experiments. It rarely has systems for decisions.
Why the Industry that governs everything else leaves its most expensive decisions ungoverned.
We have built remarkable systems for running experiments.
Target discovery platforms. Screening systems. Preclinical frameworks. Clinical plans. Regulatory pathways. Vendor ecosystems. Data lakes. AI tools.
Every one of these systems governs something; how an experiment is conducted, how external work is delivered, how a study is executed, how resources are allocated.
“But what governs the decision to proceed? What governs the decision to pause? What governs the decision to stop?”
In most organisations, those decisions emerge through discussion. Through meetings. Through accumulated confidence.
Not through governance.
Why this matters now
Consider a situation most R&D leaders will recognize immediately.
Early signalsEncouraging evidence from the target.
Molecule statusSeveral candidates appear promising
External viewExpert opinion is supportive
Internal stateTeam is enthusiastic, capital is available
At this point, most organisations have systems capable of generating more information. What they often lack is a system capable of determining whether the programme has actually earned the right to advance.
That distinction is not a philosophical one. It is an operational one, and it carries real financial consequence.
The environment progression decisions live inside
Progression decisions do not happen in neutral conditions. They happen inside environments of optimism, sunk cost, strategic pressure, scientific excitement, timeline commitments, investor expectations, and organisational momentum.
When those forces accumulate, continuation becomes the default. Not because the evidence is sufficient. Because the organization has no structured mechanism for determining when evidence becomes permission.
“More information can create more confidence without creating more certainty. Confidence supports a narrative. Certainty requires evidence.”
The industry often assumes that better information leads to better decisions. Sometimes it does. Sometimes it creates more sophisticated reasons to continue investing in programs that have not yet earned continuation.
What is actually at stake
What organizations have systems for
- How experiments are conducted
- How vendors deliver work
- How studies are executed
- How resources are allocated
- How portfolios are reviewed
What rarely has a system
- When evidence becomes permission
- What blocks progression
- Who owns the decision
- What record explains the verdict
- When to pause, stop, or re-baseline
Every meaningful progression decision consumes resources that cannot easily be recovered: capital, time, organisational attention, vendor capacity, scientific opportunity, strategic flexibility.
Before those resources are committed, organisations should be able to answer one simple question:
What specific evidence has earned the right to proceed? Not what do we believe. Not what do we hope. Not what have we already invested. What has been sufficiently established to justify the next commitment?
Where the industry is heading
Drug development will not be differentiated in the future solely by the ability to generate information. Platforms for generating data, hypotheses, and predictions are proliferating rapidly. The gap is not information volume.
The companies that create the greatest value may not be those that run the most experiments. They may be those that most effectively distinguish between activity and permission.
In drug development, success is rarely determined by the volume of work performed.
It is determined by the quality of the decisions that determine what work deserves to continue.
For leaders across R&D, BD, portfolio strategy, and investment governance:
How does your organization currently determine when evidence becomes permission?
And who owns that decision?
